Study Evaluating Approach to Treatment of Haemophilia A and B in Spain

Wyeth is now a wholly owned subsidiary of Pfizer52 enrolled

Overview

Analyze the clinical and therapeutic approach to treatment of haemophilia A and B in habitual clinical practice conditions in Spain.

Analyze the clinical and therapeutic approach to treatment of haemophilia A and B in habitual clinical practice conditions in Spain during the first 3 years since diagnosis. Assess haemophilia A or B patient profile, study different kinds of hanitual clinical treatment of haemophilia A and B patients, and estimate the kind of treatment and dosage units used per year in patients under habitual clinical practice conditions.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hemophilia A Hemophilia B

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Haemophilia A or B patients of any age * Written informed consent

Outcomes

Primary Outcomes

Analyze the clinical and therapeutic approach to treament of haemophilia A and B in habitual clinical practice conditions in Spain during the first 3 years since diagnosis.

Time frame: 3 months

Secondary Outcomes

Assess haemophilia A or B patient profile, study different kinds of habitual clinical treatment of haemophilia A and B patients, and estimate the dosage units used per year in patients under habitual clinical practice conditions.

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.